Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patientsFrançois Danion, Christelle Sordet, Jean Sibilia et al.|RMD Open|2017Cited by 29
B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologicsRenaud Felten, Jacques‐Eric Gottenberg, Pierre‐Marie Duret et al.|Annals of the Rheumatic Diseases|2021Cited by 20
Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016–2017Pauline Richebé, Raphaèle Séror, Guillaume Coiffier et al.|Annals of the Rheumatic Diseases|2022Cited by 13
Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritidesRenaud Felten, Jean-Hugues Salmon, M. Geoffroy et al.|Joint Bone Spine|2022Cited by 1
Implémentation d’un Parcours « Lupus systémique » intégratif en AlsaceMarc Scherlinger, J. Sibilia, Yannick Dieudonné et al.|Revue du Rhumatisme|2024Cited by 0